TriangleNCT01546038 · OUTCOME
Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- pg/mL
- Interval / dispersion
- Full Range
- Time frame
- Cycle 1/Day 1, 1 Hour Post dose
What was measured
Serum levels were determined for 38 circulating proteins. Selected value showing statistically significant difference compared with baseline is reported here.
Analysis population: PD analysis set: all enrolled participants in the Phase 2 Unfit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.
Groups in this outcome
Phase 2 Unfit: Glasdegib 100 mg + LDAC
Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.
| Group | Source count |
|---|---|
| Phase 2 Unfit: Glasdegib 100 mg + LDAC | 18 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 2 Unfit: Glasdegib 100 mg + LDAC | 483.00 | Not reported | 40.00 | 1230.00 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 40.00
- upper Limit
- 1230.00
- value
- 483.00
- denoms
- counts
- group Id
- OG000
- value
- 18
- units
- Participants
- description
- Serum levels were determined for 38 circulating proteins. Selected value showing statistically significant difference compared with baseline is reported here.
- dispersion Type
- Full Range
- groups
- description
- Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.
- id
- OG000
- title
- Phase 2 Unfit: Glasdegib 100 mg + LDAC
- param Type
- MEDIAN
- population Description
- PD analysis set: all enrolled participants in the Phase 2 Unfit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.
- reporting Status
- POSTED
- time Frame
- Cycle 1/Day 1, 1 Hour Post dose
- title
- Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1
- type
- SECONDARY
- unit Of Measure
- pg/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice